Dr. Paul Corkery:

We do that. The most recent example of that is in the delegated act on reserving certain antimicrobials for human use. Based on the feedback from our stakeholders, we believed they would be better served with as many products to treat animals as possible. We also believed that only products, especially antimicrobials that were required for human use and for which we had alternatives for animal health, would be designated as for human use only. There is a product we are concerned about and we have had feedback from our equine stakeholders on it. It is an antibiotic called rifampin that is used to treat rhodococcus equi pneumonia and that is the only antimicrobial that works for that condition. We are hopeful that with the delegated act we will have that taken into account along with other animal welfare issues and that we will still be able to use that product. I take the Deputy's point.